Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
about
p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistancec-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective studyTopoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipatedDistinct genes related to drug response identified in ER positive and ER negative breast cancer cell linesAmplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness.Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.Biological and clinical significance of HER2 overexpression in breast cancer.Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinomaIntegrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patientsTesting for HER2 in Breast Cancer: A Continuing Evolution.Comprehensive copy number profiles of breast cancer cell model genomes.Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.DNA topoisomerase II as a target for cancer chemotherapy.Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer SubsetQuantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.Novel molecular markers of malignancy in histologically normal and benign breastIdentifying and validating causal genetic alterations in human breast cancer.HER-2/neu and topoisomerase IIalpha in breast cancer.Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.Underuse of anthracyclines in women with HER-2+ advanced breast cancer.TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancerType 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4Targeted therapy in breast cancer: the HER-2/neu gene and protein.Allelic imbalance at the HER2/TOP2A locus in breast cancerTopoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.Comparison of whole genome amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin-fixed paraffin-embedded tissueMultiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status.Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells.Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer
P2860
Q21261313-E4422E12-1C3C-4C8E-84DF-A886C0A6C3D1Q24810266-082557BA-3E4F-4019-BC78-46FF2D3D0140Q28186346-8516BEF4-9947-4844-9928-1D4963780F08Q28481323-558C705F-B40B-49D9-94F4-1C62663F1E88Q30986520-4EA5032C-8CB7-4593-B441-01470AC60FACQ31038214-17A9170E-0D82-411D-B208-4D1E10DF3080Q31048088-BA80ECC0-2988-40AB-85CD-05DE07140AD5Q31950781-4034DA38-C9DE-478B-A041-778545606B04Q33390513-E1AF1691-E1A8-405D-A07E-1A055DAB1149Q33739397-C7B99EFD-D16B-421B-9F3B-A224B98E3B55Q33816025-0FAF7F6B-3A95-44FF-AFAB-CA118B89DC30Q34044864-6F0F6794-D369-414A-A71C-E4C070DEC162Q34390516-B8D425D1-30FA-4F59-8095-C07A2F96B8A8Q34417532-E5E9A6B2-55FD-4FB7-ACB5-8C4DD5A06A9FQ34417986-7AF4F029-8619-484B-BFF4-D2FFCCE5A376Q34424285-9BB68763-6662-4391-8C6D-5B5B00ACBA12Q34480698-893279E8-0776-4B4A-94CF-680E68062F27Q34554455-38E326B1-B216-4CD0-8540-E5F1DF1CA5B4Q34718447-3CFF9112-BEBA-49E4-AB4F-EFBDDD0C7384Q34743488-76648E25-FC87-43F9-AD0C-55EACB0ED47FQ34760593-D048B2AA-0A28-45D8-9C1A-ED0F182B3986Q34805496-3A057049-A5CC-430D-AEB8-A05BBBC22004Q35021644-CDEC3280-C954-4099-A350-ACED6192CEBBQ35029573-66FF156B-AD04-420C-85B4-F52C7325C879Q35117680-6AAFC381-A485-409E-9A58-794877EC30C2Q35130673-C5E36464-E5AE-4A71-A133-B78EFB11B53DQ35130680-F9495CD8-2AEC-4E42-B058-0309ADB41514Q35496577-18595E1D-C4A7-4D3D-A4E9-03849BC28153Q35584166-3F54E860-B74D-46DD-9CF0-DEC070171CAEQ35584659-BC735EEC-4996-4ABA-BF83-9E05523A057BQ35586732-356D0B72-8E1C-46DF-AED8-45C0B3501224Q35648508-4746ABE1-CD33-45AE-9562-216C1DFCAE76Q35663036-CB61E890-07F7-4794-923F-7D1119CE1BE2Q35770478-167F5298-C067-46A6-B8C4-E04328655144Q35788601-644459D1-8477-418D-A976-0F5764D5ED91Q35835151-04AE5CFB-04F7-45F8-88E5-22DDF4B2380AQ35864247-BB27F915-E043-47F0-BDD6-A72068779BBAQ35866923-182C76BF-824D-49B4-9D04-88E9BBD6A61FQ36016235-7EF2CBA0-1538-47DE-B1A3-BF227FFEE5E0Q36051500-0B909CE3-E3C0-4861-A955-CACA2D6C8FC8
P2860
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Amplification and deletion of ...... doxorubicin in breast cancer.
@ast
Amplification and deletion of ...... doxorubicin in breast cancer.
@en
type
label
Amplification and deletion of ...... doxorubicin in breast cancer.
@ast
Amplification and deletion of ...... doxorubicin in breast cancer.
@en
prefLabel
Amplification and deletion of ...... doxorubicin in breast cancer.
@ast
Amplification and deletion of ...... doxorubicin in breast cancer.
@en
P2093
P2860
P1476
Amplification and deletion of ...... doxorubicin in breast cancer.
@en
P2093
T A Järvinen
V Rantanen
P2860
P304
P356
10.1016/S0002-9440(10)64952-8
P407
P577
2000-03-01T00:00:00Z